TD Asset Management Inc. raised its stake in shares of Bruker Co. (NASDAQ:BRKR) by 7.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 488,268 shares of the medical research company’s stock after buying an additional 35,500 shares during the period. TD Asset Management Inc. owned 0.31% of Bruker worth $14,526,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Koch Industries Inc. raised its holdings in Bruker by 2,573.5% during the second quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock valued at $324,000 after buying an additional 322,252 shares in the last quarter. AJO LP bought a new position in Bruker during the second quarter valued at about $46,075,000. Cubist Systematic Strategies LLC raised its holdings in Bruker by 186.3% during the second quarter. Cubist Systematic Strategies LLC now owns 16,478 shares of the medical research company’s stock valued at $475,000 after buying an additional 10,723 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Bruker by 6.8% during the second quarter. Victory Capital Management Inc. now owns 1,930,209 shares of the medical research company’s stock valued at $55,667,000 after buying an additional 123,322 shares in the last quarter. Finally, Verition Fund Management LLC grew its position in shares of Bruker by 95.6% in the second quarter. Verition Fund Management LLC now owns 26,891 shares of the medical research company’s stock valued at $776,000 after purchasing an additional 13,140 shares during the last quarter. Institutional investors own 65.58% of the company’s stock.

In other Bruker news, VP Mark Munch sold 21,061 shares of Bruker stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total transaction of $631,198.17. Following the completion of the sale, the vice president now owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 35.20% of the stock is currently owned by insiders.

Several brokerages have recently issued reports on BRKR. Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research report on Wednesday, November 8th. Bank of America raised Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price on the stock in a research report on Friday, November 3rd. BidaskClub downgraded Bruker from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Cowen reissued a “hold” rating and set a $29.00 target price on shares of Bruker in a research report on Friday, November 3rd. Finally, J P Morgan Chase & Co raised Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 target price on the stock in a research report on Friday, November 3rd. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $29.64.

Bruker Co. (NASDAQ BRKR) opened at $34.81 on Friday. The company has a quick ratio of 1.60, a current ratio of 2.60 and a debt-to-equity ratio of 0.65. Bruker Co. has a one year low of $21.03 and a one year high of $36.53. The stock has a market cap of $5,472.70, a P/E ratio of 30.07, a PEG ratio of 2.97 and a beta of 1.11.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.02. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The firm had revenue of $435.60 million during the quarter, compared to analysts’ expectations of $415.45 million. During the same quarter in the previous year, the company posted $0.32 EPS. Bruker’s revenue was up 10.6% on a year-over-year basis. sell-side analysts forecast that Bruker Co. will post 1.19 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 22nd. Shareholders of record on Monday, December 4th will be issued a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend is Friday, December 1st. Bruker’s dividend payout ratio is presently 17.02%.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/td-asset-management-inc-purchases-35500-shares-of-bruker-co-brkr/1738373.html.

About Bruker

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.